PCSK9i can potentially benefit patients with either metabolic disorder as these medications could increase the clearance of LDL from the circulation, helping improve NAFLD symptoms while lowering the PCSK9 protein level commonly elevated in PCOS patients [83]. The gene discussed is PCSK9; the disease is metabolic dysfunction-associated steatotic liver disease.